In summary, because the dynamic tests are more reliable methods of assessing changes in BCF than are the homeostatic tests, it seems reasonable to assume that GLP-1RAs are more likely capable of restoring physiological β-cell insulin secretion patterns in all stages of glucose intolerance, as compared with insulin and other antidiabetes therapies. The gene discussed is INS; the disease is Glucose intolerance.